drugset / Trial / NCT01831011

Mildronate for Acute Ischemic Stroke

NCT01831011

Phase 2 Completed 227 enrolled Xijing Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Mildronate an inhibitor of carnitine-dependent metabolism, is considered an anti-ischemic drug. This study aims to evaluate the efficacy and safety of mildronate injection in treating acute ischemic stroke.

Timeline

Start
2008-07
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Meldonium Small molecule 500 mg
Comparator cinepazide Small molecule
Background Aspirin Small molecule 100 mg

Indications